Sutro Biopharma Inc
STRO
NASDAQ
Biotechnology
$20.48
USD
-0.83 (-3.89%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $360.08M
Volume 448.7K
Revenue
$45.70M
TTM
-56.3%
YoY
Gross Margin
100%
TTM
0.0%
YoY
Net Income
$-180.64M
TTM
+13.4%
YoY
Operating Cash Flow
$-145.17M
TTM
+41.7%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
Revenue | 63.7 | 9.7 | 11.6 | 14.5 | 9.8 |
YoY Growth | +148.0% | +13.8% | -21.4% | -16.5% | -84.6% |
Cost of Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Gross Profit | 63.7 | 9.7 | 11.6 | 14.5 | 9.8 |
Selling, General & Administrative | 10.3 | 8.7 | 8.7 | 7.6 | 7.8 |
Other Operating Expenses | 18.4 | 9.6 | 4.4 | 0.0 | 0.2 |
Total Operating Expenses | 67.1 | 58.2 | 49.7 | 44.2 | 39.7 |
Operating Income | -3.3 | -48.5 | -38.0 | -29.7 | -29.9 |
EBITDA | 17.0 | -37.0 | -32.0 | -28.3 | -28.4 |
Other Income / Expense | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Other Income / Expense | -8.2 | -8.4 | -8.8 | -8.8 | -8.6 |
Income Before Income Taxes | -11.5 | -56.9 | -46.8 | -38.5 | -38.5 |
Income Taxes | -0.0 | 0.0 | -0.1 | -0.0 | 0.0 |
Net Income | -11.5 | -56.9 | -46.8 | -38.5 | -38.5 |
Consolidated Net Income / Loss | -11.5 | -56.9 | -46.8 | -38.5 | -38.5 |
Net Income Attributable to Common Shareholders | -11.5 | -56.9 | -46.8 | -38.5 | -38.5 |
Basic EPS | -$1.35 | -$6.70 | -$5.42 | -$2.94 | -$2.33 |
Diluted EPS | -$1.35 | -$6.70 | -$5.42 | -$2.94 | -$2.33 |
Basic Shares Outstanding | 8.5M | 8.5M | 8.6M | 13.1M | 16.6M |
Diluted Shares Outstanding | 8.5M | 8.5M | 8.6M | 13.1M | 16.6M |